ArticleClinical rheumatology2026
Prediction nomogram of serum interferon-γ enable early identification of macrophage activation syndrome in children with Kawasaki disease.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo develop an early prediction nomogram for identifying the risk of macrophage activation syndrome (MAS) in children with Kawasaki disease (KD).
methodsThis study retrospectively collected clinical and laboratory data from KD children with MAS (KD-MAS, n = 38) between January 2019 and May 2024. Classic KD patients (KD, n = 338) and intravenous immunoglobulin (IVIG)-resistant KD patients (n = 291) were selected as control groups.
resultsChildren with KD-MAS had longer fever time, more frequent hepatomegaly and splenomegaly, and pericardial effusion, higher serum ferritin levels and lower platelet and fibrinogen levels compared with KD group and IVIG-resistant KD group. Notably, significantly increased serum interleukin-10 and interferon-γ (IFN-γ) levels were observed in children with KD-MAS. Longer fever duration (> 10 days, OR, 9.89; 95% CI 4.35-22.49), decreased platelet count (≤ 181 × 10^9/L, OR, 27.85; 95% CI 12.33-62.97), higher serum ferritin levels (> 684ug/L, OR, 112.73; 95% CI 40.74-311.88), low fibrinogen levels (≤ 3.6 g/L, OR, 33.47; 95% CI 13.16-85.13), and high IFN-γ levels (≥ 30 pg/mL, OR, 10.73; 95% CI 4.64-24.87) were independent predictors of MAS. These nomograms incorporating serum IFN-γ plus clinical variables were comparable to the classical model based on serum ferritin, platelet, and fibrinogen, underscoring the importance of serum IFN-γ as a key indicator in the early recognition of MAS in children with KD or IVIG-resistant KD.
conclusionThe prediction nomograms suggest that, within this single-center retrospective cohort, serum IFN-γ serves as a promising biomarker and plays a valuable role in the early recognition of MAS in children with KD or IVIG-resistant KD. Its combined application with prolonged fever and elevated ferritin can improve predictive efficacy. Key Points • Serum IFN-γ serves as a promising biomarker, and in conjunction with key clinical indicators, it plays a valuable role in the early recognition of MAS in children with KD or IVIG-resistant KD. • Prolonged fever (> 10 days), low platelets (≤ 181 × 10⁹/L), high ferritin (> 684 μg/L), and low fibrinogen (≤ 3.6 g/L) are significant clinical indicators of MAS. • A nomogram incorporating IFN-γ and clinical variables performs comparably to classic models, highlighting its utility in early MAS detection.
Indexed as
Identifiers
41225240What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.